乳二烯在治疗间歇性囊炎:一个回顾性试点研究
Luigi Rosa1, Antimo Cutone2, Giusi Ianiro2
1Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
概括
牛乳酸 (bLf) 在治疗疼痛性膀综合征 (PBS),也称为间歇性囊炎 (IC) 方面表现有前途. 这项试点研究发现,bLf显著减少了女性的IC/PBS发作和膀炎症.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 间歇性囊炎 (IC) 或疼痛性膀综合征 (PBS) 是一种导致膀疼痛和尿急的慢性疾病.
- 目前,IC/PBS没有确定的治疗方法,需要研究有效的治疗方法.
- 遗传性血栓性 (HT) 是一种影响血液凝固的疾病,在本研究人群中也进行了评估.
研究的目的:
- 评估牛乳酸 (bLf) 在治疗IC/PBS的妇女中的疗效和安全性.
- 评估bLf治疗对炎症标志物和膀外观的影响.
- 为了探索与同时存在的遗传性血栓性病 (HT) 患者的潜在益处.
主要方法:
- 一项追溯试点研究,涉及31名被诊断患有IC/PBS的女性.
- 治疗涉及17周口服Valpalf®囊,其中包括bLf,碳酸和酸盐.
- 对患者进行IC/PBS发作,血清炎症标志物 (IL-6,D-二次体) 的监测,并进行囊镜检查.
主要成果:
- 观察到IC/PBS发作显著减少,31名女性中有28名没有出现复发.
- 在遗传性血栓友爱症小组中,在治疗后注意到血清IL-6和D-二次体的显著下降.
- 囊镜检查显示了膀外观的整体改善,包括减少炎症,刺激和更少的汉纳.
结论:
- 口服bLf治疗似乎是缓解IC/PBS症状的有效和安全选择.
- bLf可能调节炎症通路,正如HT组IL-6和D-二次数减少所表明的那样.
- 进一步的随机对照试验是有必要的,以在更大的患者队列中证实这些发现.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
151
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
151
Drugs for Treatment of Diarrhea-Predominant IBS
156
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
156
Cystic Fibrosis: Management
151
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
151
Irritable Bowel Syndrome III: Medical and Nursing Management
189
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
189
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331


